| Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response S Jernström, V Hongisto, SK Leivonen, EU Due, DS Tadele, H Edgren, ... Breast Cancer: Targets and Therapy 9, 185, 2017 | 42 | 2017 |
| Early response evaluation by single cell signaling profiling in acute myeloid leukemia BS Tislevoll, M Hellesøy, OHE Fagerholt, SE Gullaksen, A Srivastava, ... Nature communications 14 (1), 115, 2023 | 23 | 2023 |
| Frequency-dependent ecological interactions increase the prevalence and shape the distribution of pre-existing drug resistance J Maltas, DS Tadele, A Durmaz, CD McFarland, M Hinczewski, JG Scott bioRxiv, 2023.03. 16.533001, 2023 | 11 | 2023 |
| GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells B Zhang, P Ayuda-Durán, L Piechaczyk, Y Fløisand, MM Safont, ... haematologica 104 (5), e229, 2019 | 9 | 2019 |
| Phenotypic deconvolution in heterogeneous cancer cell populations using drug-screening data A Köhn-Luque, EM Myklebust, DS Tadele, M Giliberto, L Schmiester, ... Cell Reports Methods 3 (3), 2023 | 8 | 2023 |
| A cell competition-based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation DS Tadele, J Robertson, R Crispin, MC Herrera, M Chlubnova, ... Journal of Biological Chemistry, 100179, 2021 | 7 | 2021 |
| Spatial cumulant models enable spatially informed treatment strategies and analysis of local interactions in cancer systems S Hamis, P Somervuo, JA Ågren, DS Tadele, J Kesseli, JG Scott, M Nykter, ... Journal of mathematical biology 86 (5), 68, 2023 | 4 | 2023 |
| Diverse mutant selection windows shape spatial heterogeneity in evolving populations ES King, DS Tadele, B Pierce, M Hinczewski, JG Scott PLOS Computational Biology 20 (2), e1011878, 2024 | 2 | 2024 |
| Clinical forecasting of acute myeloid leukemia using ex vivo drug-sensitivity profiling AN Andersen, AM Brodersen, P Ayuda-Durán, L Piechaczyk, DS Tadele, ... Cell Reports Methods 3 (12), 2023 | 2 | 2023 |
| Using birth-death processes to infer tumor subpopulation structure from live-cell imaging drug screening data C Wu, EB Gunnarsson, EM Myklebust, A Köhn-Luque, DS Tadele, ... arXiv preprint arXiv:2303.08245, 2023 | 2 | 2023 |
| GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells B Zhang, PA Durán, L Piechaczyk, Y Fløisand, MMS Safont, IT Karlsen, ... Haematologica, 2018 | 2 | 2018 |
| Maintaining, masking, and mimicking selection: the interplay of cell-intrinsic and cell-extrinsic effects upon eco-evolutionary dynamics R Barker-Clarke, JM Gray, DS Tadele, M Hinczewski, JG Scott bioRxiv, 2023.03. 15.532871, 2023 | 1 | 2023 |
| Clinical Forecasting using Ex Vivo Drug Sensitivity Profiling of Acute Myeloid Leukemia AN Andersen, AM Brodersen, P Ayuda-Durán, L Piechaczyk, DS Tadele, ... bioRxiv, 2022.10. 11.509866, 2022 | 1 | 2022 |
| A 36-Dimensional Cytometry by Time of Flight (CyTOF) Analysis of De Novo Acute Myeloid Leukemia (AML) Patients Eligible for Intensive Chemotherapy BS Tislevoll, OHE Fagerholt, N Blaser, M Hellesøy, SE Gullaksen, ... Blood 132 (Supplement 1), 1502-1502, 2018 | 1 | 2018 |
| Risk Stratification of Acute Myeloid Leukemia Using Ex Vivo Drug Sensitivity Profiling AM Brodersen, AN Andersen, P Ayuda-Durán, L Piechaczyk, DS Tadele, ... | | 2022 |
| S835 MASS CYTOMETRY REVEAL EARLY SIGNALING RESPONSES TO INDUCTION THERAPY IN IMMUNOPHENOTYPICALLY DEFINED LEUKEMIC CELL SUBSETS THAT PREDICT SURVIVAL IN AML BS Tislevoll, OHE Fagerholt, M Hellesøy, SE Gullaksen, PA Duran, ... HemaSphere 3 (S1), 371-372, 2019 | | 2019 |
| A PRECISION MEDICINE PLATFORM FOR ACUTE MYELOID LEUKEMIA TO HELP UNRAVELING THE MOLECULAR ADDICTIONS OF FLT3-ITD-DRIVEN AML P Ayuda-Duran, B Zhang, L Piechaczyk, M Popa, D Tadele, A Rowe, ... HAEMATOLOGICA 102, 357-357, 2017 | | 2017 |
| Identification of alternative compounds by drug screening of HER2 positive breast cancer cell lines. S Nyberg, V Hongisto, DS Tadele, H Edgren, SK Leivonen, O Kallioniemi, ... Cancer Research 73 (8 Supplement), 2107-2107, 2013 | | 2013 |
| 5003 ORAL Inhibition of HER2 Positive Breast Cancer Cells by Drug Screening S Nvberq, V Hongisto, DS Tadele, SK Leivonen, H Edgren, O Kallioniemi, ... European Journal of Cancer, S330-S331, 2011 | | 2011 |
